2seventy bio, Inc.
TSVT
$0.06
Change (1 day)
$6.40
Year High
$1.54
Year Low
Categories
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Earnings for 2seventy bio, Inc. (TSVT)
Earnings in 2023 (TTM): $-217,570,000
According to 2seventy bio, Inc.'s latest financial reports the company's current earnings (TTM) are $-217,570,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of 2seventy bio, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-217,570,000 | $-217,570,000 |
| 2022 | $-254,153,000 | $-254,144,013 |
| 2021 | $-292,213,000 | $-276,214,000 |
| 2020 | $-120,114,000 | $-138,170,000 |
| 2019 | $-320,594,000 | $-323,341,000 |
| 2018 | $-199,749,000 | $-199,749,000 |